Business
Trading Update
Surgical Innovations Group plc anticipates revenues of approximately £11.5 million for the year ending 31 December 2025, a figure lower than expected due to softer sales in the final quarter. This downturn is attributed to external factors including a global flu epidemic impacting elective procedures across key markets, compounded by NHS industrial action. Additionally, a one-off quality issue with OEM components temporarily constrained manufacturing, though supply is now resuming. The company has also increased its provision for slow-moving raw material stock. Net debt stood at £0.4 million as of 17 December 2025. Disclaimer*
About this update from Surgical Innovations Group Plc
Surgical Innovations Group plc ("Surgical Innovations", the "Company", or the "Group") Trading update Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery, provides the following update on trading ahead of its year ended 31 December 2025. Sales in the final quarter have been softer than anticipated due to a number external factors including: · The global flu epidemic is impacting the Group across its key markets in Europe, APAC and ROW and has led to a reduction in elective surgical procedures. · This has been compounded by continued industrial action in the NHS taking place in September and further strikes scheduled for next week, contributing to additional delays in elective procedures and increased seasonal pressure on NHS capacity. · Sales in December have also been adversely affected by a one-off quality issue relating to key components supplied by an OEM partner, which constrained our manufacturing of their product. The issues have been promptly addressed and supply is resuming, with normal deliveries expected in early 2026. As a result of these unanticipated market factors, the Company expects revenues for the year to now be c. £11.5m with a commensurate impact on profits. In addition, as part of its review of year-end inventory holdings, the Board has taken the prudent decision to increase its provision held against slow moving raw material stock. Net debt as of 17 December 2025 was £0.4m and the Company continues to closely monitor its working capital position. The Board remains confident of the growing focus on environmental sustainability driving organisations to adopt greener practices, with Surgical Innovations well positioned to capitalise on offering a sustainable solution with the Company's reposable™ technology aligning with this shift. David Marsh, CEO of Surgical Innovations, said: "Whilst we are naturally disappointed with the external market forces having a direct impact on the Group's performance, we remain confident in our reposable™ technology and the overall prospects of the Group going forward. We look forward to updating shareholders at our full year results." For further information please conta...
View stock analysis, news, and events for Surgical Innovations Group Plc